Assessment the Effect of Fomoterol and Budesonide Combination in Moderate and Severe Asthmatic Patients Admitted to Ahvaz Imam Hospital-Iran

Document Type : Original Article

Authors

1 Pharm.D,Student Research Center, School of Pharmacy,Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Assistant Professor of Immunology.Department of Immunology, Cellular and Molecular Research Center, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Associate Professor of Pharmaceutics.Department of Pharmaceutics, School of Pharmacy, Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

4 Associate Professor of Internal Medicine.Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

5 Assistant Professor of Medical Genetics.Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

6 Cardiologist.Department of Cardiology, School of Medicine, University of Medical Sciences, Ahvaz, Ahvaz, Iran.

Abstract

Background and Objective: New combinations of drugs are used for asthma control, which aim to achieve lack of symptoms and increase pulmonary function with the least amount of drug administration. In this study, the clinical recovery of pulmonary function in asthmatic patients before and after two weeks of treatment with a combination of fomoterol and budesonide compared.
Subjects and Methods: This study was carried out on 58 newly diagnosed moderate and severe asthmatic patients referred to Ahvaz Imam Hospital during the first six months of the 2012. Physical examination and FVC, FEV1 and PEF variables were assessed using spirometry. After two weeks treatment with a combination of fomoterol (320µg) and budesonide (9µg) turbohaler the patients were re-evaluated. SPSS analysis software and ANOVA (t-test) methods were used for data analysis. 
Results: The mean FEV1 before treatment was 2.92±1.2 which increased to 3.1±0.78 after treatment ((P<0.05). The FVC before treatment was 3.51±1.4 also increased significantly after treatment 3.87± 0.98 (P<0.05). On the other hand, PEF percentage for pre-treatment was 1.8 ± 4.50 %, which significantly increased to  4.98±0.6% after treatment (P <0.05).
Conclusion: The use of the combination of formetrol plus budesonide for the treatment of moderate and severe asthma was found to be useful in clinical and can achieve satisfactory control of moderate and severe asthma.
 

Keywords

References

1-Peter J, Anthony S, Fauci Braunwald, K. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill, c; 2008:1596-607.
2-Lewis H. Text book of medical surgical assessmentand management of clinical problem. 5th ed Sydney: Mosby; 2000: 660.
3-Carroll P. How to intervene before asthma turns deadly. RN 2001; 64(5): 52-8.
4-World Health Organization Fact:athma. 2011 sheet No 307.
5-Hassanzadeh J,  Mohammadbeigi A,  Mousavizadeh A. Asthma prevalence in Iranian guidance school children, a descriptive meta-analysis. J Res Med Sci Mar 2012; 17(3): 293–7.
6-Ghanei M, Aslani J, Aghaee meybodi SM. Efficacy Determination of Azithromycin and Prednisolone Protocol Treatment in Refractory Asthma. J Mil Med 2007; 9(3) :159-66.
7-Rosenhall L, Ekvstrand A, Tillingz B. One-year safety and e⁄cacy of budesonide/formoterol in a single inhaler (Symbicorts Turbuhalers) for the treatment of asthma. 2003.97: 702-708.
8-Saba MA, Taghadosi M, Kasaee SS, Akbari H. The effect of concomitant administration of furosemide and salbutamol on spirometry parameters in persistent asthma. Feyz 2013; 17(2): 123-31.

9-JIANG Cheng-Cheng. Comparison of the efficacy of inhaled-powder budesonide/formoterol with the efficacy of inhaled-powder salmeterol/fluticasone on asthma. Chinese Journal 2011.

10-Kim SH, Ye YM, Lee HY, Sin HJ, Park HS. Combined pharmacogenetics effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther 2011 Jun;36(3):399-405.

11-Giubergia V, Gravina LP, Castaños C, Chertkoff L, Grenoville M. Influence of beta2-adrenoceptor polymorphisms on the response to chronic use of albuterol in asthmatic children. Pediatr Pulmonol 2008 May;43(5):421-5.
12-Adimi Naghan P, Fahimi F, Nadji SA, Naderi N, Soleimani  F, Masjedi MR. A Pilot Study of Polymorphism of Adrenergic Beta-2 Receptor and Mild Asthma: A Clinical and Pharmacogenetics Study.  Iranian Journal of Pharmaceutical Research 2013, 12 (1): 199-204.
13-Soleimani F, Fahimi F, Adimi Naghan P, Nadji SA, Morowati S, Naderi N, et al. The Effect of Polymorphisms of Beta2 Adrenoceptors on Response to Long-acting Beta2 Agonists in Iranian Asthmatic Patients. Iran J Allergy Asthma Immunol.December 2013; 12(4):383-90.
14-Poziomkowska-Gesicka I, Gawlikowska-Sroka A, Dzieciolowska-Baran E, Teul I, Adler G, Ciechanowicz A, et al. β2-adrenergic receptor gene polymorphism and response to bronchodilation treatment evaluated by spirometry. Adv Exp Med Biol 2013;755:169-77.
15-Baur X, Aasen TB, Burge PS, Heederik D, Henneberger PK. The management of work-related asthma guidelines: a broader perspective. European respiratory review. Jun 2012; 21 (124): 125–39.

16-Hui Z, Fu-yang P, He L. Comparison of therapeutic efficiency of Sere tide plus Montelukast and Sere tide only in patients with severe persistent asthma. Chinese Journal 2009.

17-Khalilzadeh S, Bloorsaz M, Safavi A, Masjedi M. Efficacy and safety of inhaled steroids in children with asthma: a comparison of Fluticasone Propionate with Beclomethasone. Pejouhesh 2006; 30 (3) :201-5.

Jundishapur Scientific Medical Journal
Volume 15, Issue 3 - Serial Number 102
July and August 2017
Pages 315-322

Files

History

  • Receive Date: 25 January 2015
  • Accept Date: 02 July 2016

Share

How to cite

Statistics